NCT02246075 is a Phase 2 clinical trial of EVP-6124 in Alzheimer's Disease, sponsored by FORUM Pharmaceuticals Inc.

Who is sponsoring NCT02246075?

NCT02246075 is sponsored by FORUM Pharmaceuticals Inc.

What drugs are being tested in NCT02246075?

Interventions in NCT02246075: EVP-6124.

What condition does NCT02246075 study?

NCT02246075 studies Alzheimer's Disease, Dementia, Cognition.

Is NCT02246075 still recruiting?

NCT02246075 is currently withdrawn. Last updated 13 October 2015.

Last reviewed 2015-10-13 · How we verify

NCT02246075

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, 24-Week, Phase 2 Study of Two Doses of EVP-6124 Hydrochloride or Placebo in Subjects With Mild to Moderate Alzheimer's Disease Currently Receiving Memantine Medication With or Without Additional Acetylcholinesterase Inhibitor Co-Medication

Withdrawn Phase 2 Last updated 13 October 2015

What this trial tests

Phase 2 trial testing EVP-6124 in Alzheimer's Disease. Withdrawn.

Timeline

1 July 2015

Primary endpoint
1 October 2016

Quick facts

Lead sponsor	FORUM Pharmaceuticals Inc
Phase	Phase 2
Status	Withdrawn
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	quadruple
Primary purpose	treatment
Start date	1 July 2015
Primary completion	1 October 2016
Sites	2 locations across United States

Drugs / interventions tested

EVP-6124 — full drug profile →

Conditions studied

Alzheimer's Disease — all drugs for Alzheimer's Disease →
Dementia — all drugs for Dementia →
Cognition — all drugs for Cognition →

Sponsor

FORUM Pharmaceuticals Inc — full company profile →

Who can join

Adults 55 to 85, any sex, with Alzheimer's Disease or Dementia. Patients with the condition only — healthy volunteers not accepted.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

Safety/Tolerability of EVP-6124 with concurrent memantine
Time frame: Baseline to Day 168
* Number of subjects with AEs * Percentage of subjects with AEs * Number of subjects with SAEs * Percentage of subjects with SAEs * Number of subjects who discontinue due to AEs * Percentage of subjects who discontinue due to AEs * Number of subject deaths * Percentage of subject deaths

Sponsor's own description

The purpose of this study is to evaluate the safety of 2 fixed doses of EVP-6124 hydrochloride (HCl) compared to placebo for 24 weeks in subjects with mild to moderate Alzheimer's disease who are concurrently receiving stable treatment with memantine and currently receiving stable treatment or previously treated with an acetylcholinesterase inhibitor.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

A Systematic Review on Drugs Acting as Nicotinic Acetylcholine Receptor Agonists in the Treatment of Dementia.
Crestini A, Carbone E, Rivabene R, Ancidoni A, et al · · 2024 · cited 11× · PMID 38334629 · DOI 10.3390/cells13030237

Verify or expand the search:

Other recruiting trials for Alzheimer's Disease

Currently open trials in the same condition.

NCT07457138 — Lombard Cohort of Brain Health Services · recruiting
NCT07234942 — A Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO7812653 in Participants Wit · Phase 1 · recruiting
NCT07479914 — Art of Memory for Cognitive Enhancement in the Monza Brain Health Service · NA · active not recruiting
NCT07214727 — A Study to Evaluate ALN-5288 in Patients With Alzheimer's Disease · Phase 1 · recruiting
NCT07105709 — Open-label Extension Study in Participants With Early Alzheimer's Disease · Phase 2 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT02246075 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by FORUM Pharmaceuticals Inc
Last refreshed: 13 October 2015

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02246075.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing